IRBM
A contract research organization working across all aspects of drug discovery and early development for different modalities.
The company has collaborations with organizations from the pharmaceutical, biotech and academic sectors, helping to accelerate drug discovery from target validation and hit identification to candidate nomination.
IRBM has discovered several drugs that are on the market, and more than 25 compounds have gone into clinical testing. The company was founded in 2010, as a spin-off from MSD.
Latest IRBM News & Features
23 June 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze